ReviewFrontiers in physiology2020
Recent Advances in the Treatment of Sickle Cell Disease.
Review in Frontiers in physiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 2 syntheses or guidelines pooled it, 190 citations in OpenAlex.
- Genetic polymorphisms and protein levels in vocal fold leukoplakia: a systematic review.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2022Pooled it
- Depression in adults with sickle cell disease: a systematic review of the methodological issues in assessing prevalence of depression.BMC psychology · 2021Pooled it
- The GLOBE Trial: Efficacy and Safety of L-Glutamine Plus Hydroxyurea Versus Hydroxyurea Alone in Sickle Cell Anemia - A Double-Blind, Randomized StudyTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026Trial
- Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease.Blood advances · 2024Trial
- Reactive Oxygen Species in Cardiovascular and Hematological Diseases: Mechanisms and Therapeutic Strategies.Cureus · 2026Review
- Retinal Challenges in Sickle Cell Patients-Present and Future: A Systematic Review.Bioengineering (Basel, Switzerland) · 2026Review
- Genetic Contribution to Asthma Informs Acute Chest Syndrome Pathophysiology and Risk Stratification.American journal of hematology · 2026Article
- Updated Review of Current Therapeutic Approaches for the Management of Sickle Cell Disease.Cardiovascular & hematological disorders drug targets · 2026Review
- "I think if we don't eat well, we will be sicker": a qualitative perspective on contributing factors to diet intake and nutrition among adults living with SCD in the United States.Journal of sickle cell disease · 2026Article
- Lipid nanoparticle-mediated mRNA delivery to CD34Nature biotechnology · 2025Article
- Adhesion molecules in focus: mechanistic pathways and therapeutic avenues in sickle cell vaso-occlusion - a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Long-term mitapivat treatment is safe and efficacious in patients with sickle cell disease.Blood red cells & iron · 2025Article
- Real-World Experience of L-Glutamine in Sickle Cell Disease: A Retrospective Observational Study.Pharmacy (Basel, Switzerland) · 2025Article
- Efficacy and safety of thalidomide with hydroxyurea in sickle cell anemia: a quasi-experimental clinical trial.Blood research · 2025Article
- Managing emotional and physical stress in sickle cell anemia: a review of effective strategies and approaches.Annals of medicine and surgery (2012) · 2025Review
- Promising role of voxelotor in managing sickle cell disease in children: a narrative review.Clinical and experimental pediatrics · 2025Article
- Article
- Beyond the traditional oncology patient: the role of palliative care in patients with sickle cell disease receiving stem cell transplantation or gene therapy.Frontiers in oncology · 2025Article
- Sickle cell disease: understanding pathophysiology, clinical features and advances in gene therapy approaches.Frontiers in pharmacology · 2025Review
- Genomics-driven drug repurposing and novel targets identification for sickle cell disease in Saudi patients.Frontiers in bioinformatics · 2025Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sickle cell anemia (SCA) was first described in the Western literature more than 100 years ago. Elucidation of its molecular basis prompted numerous biochemical and genetic studies that have contributed to a better understanding of its pathophysiology. Unfortunately, the translation of such knowledge into developing treatments has been disproportionately slow and elusive. In the last 10 years, discovery of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.